Filing Details
- Accession Number:
- 0000880771-17-000056
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2017-03-17 16:50:36
- Reporting Period:
- 2017-03-15
- Filing Date:
- 2017-03-17
- Accepted Time:
- 2017-03-17 16:50:36
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
880771 | Sciclone Pharmaceuticals Inc | SCLN | Pharmaceutical Preparations (2834) | 943116852 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1555794 | Lan Xie | 950 Tower Lane, Suite 900 Foster City CA 94404 | Vp Finance, China Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2017-03-15 | 1,000 | $0.00 | 1,000 | No | 4 | M | Direct | |
Common Stock | Disposition | 2017-03-16 | 1,000 | $9.60 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Restricted Stock Unit | Disposition | 2017-03-15 | 1,000 | $0.00 | 1,000 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
19,000 | 2026-03-15 | No | 4 | M | Direct |
Footnotes
- The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 18, 2016.
- Granted under the Issuer's 2015 Equity Incentive Plan.
- Each restricted stock unit represents the right to receive, at settlement, one share of common stock.
- Vesting for such RSUs will occur 25% on March 15, 2017, 25% on March 15, 2018, 25% on March 15, 2019, and 25% on March 15, 2020, contingent upon the executive's continued employment.